Cost and effects of raising the dose of myeloma drugs at home vs. hospital
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or hasn't responded to other treatments.
- You are currently taking one of these targeted drugs: teclistamab, elranatamab, or talquetamab.
- You are over 18 years old.
- You can either come to the day hospital (if you live within 30 minutes of the Oncopole and can stay for 48 hours after each dose increase) or you can be admitted to the hospital for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This trial tests if people with multiple myeloma can safely give themselves a medication called daratumumab under the skin at home, instead of going to the hospital for every dose. It aims to see if home self-administration is practical and acceptable for patients.
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
This study tests if people with relapsed multiple myeloma can safely give themselves a medicine called elranatamab at home. It aims to make treatment more convenient while still being safe and effective.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This study compares a shot under the skin to an IV infusion of the drug belantamab for people with multiple myeloma who are already on maintenance therapy after a stem cell transplant. The goal is to see if the shot works as well and is more convenient.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.